A new final guidance document from the US Food and Drug Administration offers manufacturers fundamental advice on how to prepare for and execute a product recall action.
“A firm that initiates a recall because it believes the product to be violative is requested to notify FDA immediately,” says the 3 March guidance, “Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?